Literature DB >> 29617717

Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis.

H Uno1, B Claggett2, L Tian3, H Fu4, B Huang5, D H Kim6, L J Wei7.   

Abstract

Mesh：

Year:  2018        PMID： 29617717      PMCID： PMC5961386          DOI： 10.1093/annonc/mdy109

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  6 in total

1.  Home Time as a Patient-Centered Outcome in Administrative Claims Data.

Authors:  Hemin Lee; Sandra M Shi; Dae Hyun Kim
Journal:  J Am Geriatr Soc       Date:  2018-12-21       Impact factor: 5.562

2.  Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis.

Authors:  Ariela R Orkaby; Michael W Rich; Ryan Sun; Eliah Lux; Lee-Jen Wei; Dae Hyun Kim
Journal:  J Am Geriatr Soc       Date:  2018-09-25       Impact factor: 5.562

3.  Restricted mean survival time versus conventional measures for treatment decision-making.

Authors:  Dae Hyun Kim; Sandra M Shi; Danette Carroll; Mehdi Najafzadeh; Lee-Jen Wei
Journal:  J Am Geriatr Soc       Date:  2021-04-26       Impact factor: 7.538

4.  Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib.

Authors:  Katharina Pomej; Lorenz Balcar; Bernhard Scheiner; Georg Semmler; Tobias Meischl; Mattias Mandorfer; Thomas Reiberger; Christian Müller; Michael Trauner; Matthias Pinter
Journal:  J Hepatocell Carcinoma       Date:  2021-11-30

5.  Time spent outside of the hospital, CKD progression, and mortality: a prospective cohort study.

Authors:  Lin Zhang; Heng-Lan Wu; Hai-Feng Yu; Jun-Liang Zhou
Journal:  Int Urol Nephrol       Date:  2021-01-01       Impact factor: 2.370

6.  An alternative approach for estimating the number needed to treat for survival endpoints.

Authors:  Zhao Yang; Guosheng Yin
Journal:  PLoS One       Date:  2019-10-18       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.